Controlling proteins in cells using a small molecule approach
Regulation of eDHFR-tagged proteins with trimethoprim PROTACs
This study is exploring a new way to control a specific protein in cells and animals using a special version of an antibiotic, which could help scientists better understand how proteins work and improve cancer treatments like CAR T-cell therapy by allowing them to see and manage protein activity in real time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10916289 on NIH RePORTER |
What this research studies
This research focuses on developing a method to control the expression of a specific protein tag in cells and animals using small molecules. By utilizing a modified version of the antibiotic trimethoprim, researchers aim to create a system that allows for real-time imaging and regulation of proteins involved in critical biological processes. This approach could enhance our understanding of protein functions and improve therapies, such as CAR T-cell treatments for cancer, by allowing precise control over protein behavior in living organisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment for solid tumors who may benefit from advanced CAR T-cell therapies.
Not a fit: Patients with conditions unrelated to solid tumors or those not eligible for CAR T-cell therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer therapies by improving the targeting and regulation of therapeutic proteins.
How similar studies have performed: Other research has shown promise in using small molecules for protein regulation, indicating that this approach may lead to significant advancements in therapeutic applications.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Sellmyer, Mark a — University of Pennsylvania
- Study coordinator: Sellmyer, Mark a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.